1
|
Marrer-Berger E, Nicastri A, Augustin A, Kramar V, Liao H, Hanisch LJ, Carpy A, Weinzierl T, Durr E, Schaub N, Nudischer R, Ortiz-Franyuti D, Breous-Nystrom E, Stucki J, Hobi N, Raggi G, Cabon L, Lezan E, Umaña P, Woodhouse I, Bujotzek A, Klein C, Ternette N. The physiological interactome of TCR-like antibody therapeutics in human tissues. Nat Commun 2024; 15:3271. [PMID: 38627373 PMCID: PMC11021511 DOI: 10.1038/s41467-024-47062-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Accepted: 03/19/2024] [Indexed: 04/19/2024] Open
Abstract
Selective binding of TCR-like antibodies that target a single tumour-specific peptide antigen presented by human leukocyte antigens (HLA) is the absolute prerequisite for their therapeutic suitability and patient safety. To date, selectivity assessment has been limited to peptide library screening and predictive modeling. We developed an experimental platform to de novo identify interactomes of TCR-like antibodies directly in human tissues using mass spectrometry. As proof of concept, we confirm the target epitope of a MAGE-A4-specific TCR-like antibody. We further determine cross-reactive peptide sequences for ESK1, a TCR-like antibody with known off-target activity, in human liver tissue. We confirm off-target-induced T cell activation and ESK1-mediated liver spheroid killing. Off-target sequences feature an amino acid motif that allows a structural groove-coordination mimicking that of the target peptide, therefore allowing the interaction with the engager molecule. We conclude that our strategy offers an accurate, scalable route for evaluating the non-clinical safety profile of TCR-like antibody therapeutics prior to first-in-human clinical application.
Collapse
Affiliation(s)
- Estelle Marrer-Berger
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
| | - Annalisa Nicastri
- The Jenner Institute, Old Road Campus Research Building, Oxford, OX37DQ, UK
- Centre for Immuno-Oncology, Old Road Campus Research Building, Oxford, OX37DQ, UK
| | - Angelique Augustin
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
| | - Vesna Kramar
- Roche Innovation Center Zürich, 8952, Schlieren, Switzerland
| | - Hanqing Liao
- The Jenner Institute, Old Road Campus Research Building, Oxford, OX37DQ, UK
- Centre for Immuno-Oncology, Old Road Campus Research Building, Oxford, OX37DQ, UK
| | | | - Alejandro Carpy
- Roche Pharma Research & Early Development, Roche Innovation Center Munich, 82377, Penzberg, Germany
| | - Tina Weinzierl
- Roche Innovation Center Zürich, 8952, Schlieren, Switzerland
| | - Evelyne Durr
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
| | - Nathalie Schaub
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
| | - Ramona Nudischer
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
| | - Daniela Ortiz-Franyuti
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
| | - Ekaterina Breous-Nystrom
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
| | - Janick Stucki
- Alveolix AG, Swiss Organs-on-Chip Innovation, 3010, Bern, Switzerland
| | - Nina Hobi
- Alveolix AG, Swiss Organs-on-Chip Innovation, 3010, Bern, Switzerland
| | - Giulia Raggi
- Alveolix AG, Swiss Organs-on-Chip Innovation, 3010, Bern, Switzerland
| | - Lauriane Cabon
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
| | - Emmanuelle Lezan
- Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland
| | - Pablo Umaña
- Roche Innovation Center Zürich, 8952, Schlieren, Switzerland
| | - Isaac Woodhouse
- The Jenner Institute, Old Road Campus Research Building, Oxford, OX37DQ, UK
- Centre for Immuno-Oncology, Old Road Campus Research Building, Oxford, OX37DQ, UK
| | - Alexander Bujotzek
- Roche Pharma Research & Early Development, Roche Innovation Center Munich, 82377, Penzberg, Germany
| | - Christian Klein
- Roche Innovation Center Zürich, 8952, Schlieren, Switzerland.
| | - Nicola Ternette
- The Jenner Institute, Old Road Campus Research Building, Oxford, OX37DQ, UK.
- Centre for Immuno-Oncology, Old Road Campus Research Building, Oxford, OX37DQ, UK.
- Department of Pharmaceutical Sciences, University of Utrecht, 3584, CH, Utrecht, The Netherlands.
| |
Collapse
|
2
|
Kerns JS, Belgur C, Kanellias M, Manatakis DV, Barrile R, Tien-Street W, Ewart L, Gjorevski N, Cabon L, Cabon L. Safety Profiling of Tumor-targeted T Cell-Bispecific Antibodies with Alveolus Lung- and Colon-on-Chip. Bio Protoc 2023; 13:e4579. [PMID: 36789090 PMCID: PMC9901459 DOI: 10.21769/bioprotoc.4579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 07/12/2022] [Accepted: 12/06/2022] [Indexed: 01/06/2023] Open
Abstract
Traditional drug safety assessments often fail to predict complications in humans, especially when the drug targets the immune system. Rodent-based preclinical animal models are often ill-suited for predicting immunotherapy-mediated adverse events in humans, in part because of the fundamental differences in immunological responses between species and the human relevant expression profile of the target antigen, if it is expected to be present in normal, healthy tissue. While human-relevant cell-based models of tissues and organs promise to bridge this gap, conventional in vitro two-dimensional models fail to provide the complexity required to model the biological mechanisms of immunotherapeutic effects. Also, like animal models, they fail to recapitulate physiologically relevant levels and patterns of organ-specific proteins, crucial for capturing pharmacology and safety liabilities. Organ-on-Chip models aim to overcome these limitations by combining micro-engineering with cultured primary human cells to recreate the complex multifactorial microenvironment and functions of native tissues and organs. In this protocol, we show the unprecedented capability of two human Organs-on-Chip models to evaluate the safety profile of T cell-bispecific antibodies (TCBs) targeting tumor antigens. These novel tools broaden the research options available for a mechanistic understanding of engineered therapeutic antibodies and for assessing safety in tissues susceptible to adverse events. Graphical abstract Figure 1. Graphical representation of the major steps in target-dependent T cell-bispecific antibodies engagement and immunomodulation, as performed in the Colon Intestine-Chip.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Nikolche Gjorevski
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
*For correspondence:
;
| | - Lauriane Cabon
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
*For correspondence:
;
| | | |
Collapse
|
3
|
Lewin TD, Avignon B, Tovaglieri A, Cabon L, Gjorevski N, Hutchinson LG. An in silico Model of T Cell Infiltration Dynamics Based on an Advanced in vitro System to Enhance Preclinical Decision Making in Cancer Immunotherapy. Front Pharmacol 2022; 13:837261. [PMID: 35586042 PMCID: PMC9108393 DOI: 10.3389/fphar.2022.837261] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Accepted: 03/11/2022] [Indexed: 01/04/2023] Open
Abstract
Cancer immunotherapy often involves the use of engineered molecules to selectively bind and activate T cells located within tumour tissue. Fundamental to the success of such treatments is the presence or recruitment of T cells localised within the tumour microenvironment. Advanced organ-on-a-chip systems provide an in vitro setting in which to investigate how novel molecules influence the spatiotemporal dynamics of T cell infiltration into tissue, both in the context of anti-tumour efficacy and off-tumour toxicity. While highly promising, the complexity of these systems is such that mathematical modelling plays a crucial role in the quantitative evaluation of experimental results and maximising the mechanistic insight derived. We develop a mechanistic, mathematical model of a novel microphysiological in vitro platform that recapitulates T cell infiltration into epithelial tissue, which may be normal or transformed. The mathematical model describes the spatiotemporal dynamics of infiltrating T cells in response to chemotactic cytokine signalling. We integrate the model with dynamic imaging data to optimise key model parameters. The mathematical model demonstrates a good fit to the observed experimental data and accurately describes the distribution of infiltrating T cells. This model is designed to complement the in vitro system; with the potential to elucidate complex biological mechanisms, including the mode of action of novel therapies and the drivers of safety events, and, ultimately, improve the efficacy-safety profile of T cell-targeted cancer immunotherapies.
Collapse
|
4
|
Kerns SJ, Belgur C, Petropolis D, Kanellias M, Barrile R, Sam J, Weinzierl T, Fauti T, Freimoser-Grundschober A, Eckmann J, Hage C, Geiger M, Ng PR, Tien-Street W, Manatakis DV, Micallef V, Gerard R, Bscheider M, Breous-Nystrom E, Schneider A, Giusti AM, Bertinetti-Lapatki C, Grant HS, Roth AB, Hamilton GA, Singer T, Karalis K, Moisan A, Bruenker P, Klein C, Bacac M, Gjorevski N, Cabon L. Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. eLife 2021; 10:e67106. [PMID: 34378534 PMCID: PMC8373379 DOI: 10.7554/elife.67106] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Accepted: 08/10/2021] [Indexed: 12/13/2022] Open
Abstract
Traditional drug safety assessment often fails to predict complications in humans, especially when the drug targets the immune system. Here, we show the unprecedented capability of two human Organs-on-Chips to evaluate the safety profile of T-cell bispecific antibodies (TCBs) targeting tumor antigens. Although promising for cancer immunotherapy, TCBs are associated with an on-target, off-tumor risk due to low levels of expression of tumor antigens in healthy tissues. We leveraged in vivo target expression and toxicity data of TCBs targeting folate receptor 1 (FOLR1) or carcinoembryonic antigen (CEA) to design and validate human immunocompetent Organs-on-Chips safety platforms. We discovered that the Lung-Chip and Intestine-Chip could reproduce and predict target-dependent TCB safety liabilities, based on sensitivity to key determinants thereof, such as target expression and antibody affinity. These novel tools broaden the research options available for mechanistic understandings of engineered therapeutic antibodies and assessing safety in tissues susceptible to adverse events.
Collapse
Affiliation(s)
| | | | | | | | - Riccardo Barrile
- Emulate IncBostonUnited States
- Department of Biomedical Engineering, University of CincinnatiCincinnatiUnited States
| | - Johannes Sam
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Tina Weinzierl
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Tanja Fauti
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | | | - Jan Eckmann
- Roche Pharma Research & Early Development, Roche Innovation Center MunichPenzbergGermany
| | - Carina Hage
- Roche Pharma Research & Early Development, Roche Innovation Center MunichPenzbergGermany
| | - Martina Geiger
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | | | | | | | - Virginie Micallef
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | - Regine Gerard
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | - Michael Bscheider
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | | | - Anneliese Schneider
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Anna Maria Giusti
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | | | | | - Adrian B Roth
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | | | - Thomas Singer
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | | | - Annie Moisan
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | - Peter Bruenker
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Christian Klein
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Marina Bacac
- Roche Pharma Research & Early Development, Roche Innovation Center ZurichSchlierenSwitzerland
| | - Nikolce Gjorevski
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| | - Lauriane Cabon
- Roche Pharma Research & Early Development, Roche Innovation Center BaselBaselSwitzerland
| |
Collapse
|
5
|
Delavallée L, Mathiah N, Cabon L, Mazeraud A, Brunelle-Navas MN, Lerner LK, Tannoury M, Prola A, Moreno-Loshuertos R, Baritaud M, Vela L, Garbin K, Garnier D, Lemaire C, Langa-Vives F, Cohen-Salmon M, Fernández-Silva P, Chrétien F, Migeotte I, Susin SA. Mitochondrial AIF loss causes metabolic reprogramming, caspase-independent cell death blockade, embryonic lethality, and perinatal hydrocephalus. Mol Metab 2020; 40:101027. [PMID: 32480041 PMCID: PMC7334469 DOI: 10.1016/j.molmet.2020.101027] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Revised: 05/18/2020] [Accepted: 05/27/2020] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVES Apoptosis-Inducing Factor (AIF) is a protein involved in mitochondrial electron transport chain assembly/stability and programmed cell death. The relevant role of this protein is underlined because mutations altering mitochondrial AIF properties result in acute pediatric mitochondriopathies and tumor metastasis. By generating an original AIF-deficient mouse strain, this study attempted to analyze, in a single paradigm, the cellular and developmental metabolic consequences of AIF loss and the subsequent oxidative phosphorylation (OXPHOS) dysfunction. METHODS We developed a novel AIF-deficient mouse strain and assessed, using molecular and cell biology approaches, the cellular, embryonic, and adult mice phenotypic alterations. Additionally, we conducted ex vivo assays with primary and immortalized AIF knockout mouse embryonic fibroblasts (MEFs) to establish the cell death characteristics and the metabolic adaptive responses provoked by the mitochondrial electron transport chain (ETC) breakdown. RESULTS AIF deficiency destabilized mitochondrial ETC and provoked supercomplex disorganization, mitochondrial transmembrane potential loss, and high generation of mitochondrial reactive oxygen species (ROS). AIF-/Y MEFs counterbalanced these OXPHOS alterations by mitochondrial network reorganization and a metabolic reprogramming toward anaerobic glycolysis illustrated by the AMPK phosphorylation at Thr172, the overexpression of the glucose transporter GLUT-4, the subsequent enhancement of glucose uptake, and the anaerobic lactate generation. A late phenotype was characterized by the activation of P53/P21-mediated senescence. Notably, approximately 2% of AIF-/Y MEFs diminished both mitochondrial mass and ROS levels and spontaneously proliferated. These cycling AIF-/Y MEFs were resistant to caspase-independent cell death inducers. The AIF-deficient mouse strain was embryonic lethal between E11.5 and E13.5 with energy loss, proliferation arrest, and increased apoptotic levels. Contrary to AIF-/Y MEFs, the AIF KO embryos were unable to reprogram their metabolism toward anaerobic glycolysis. Heterozygous AIF+/- females displayed progressive bone marrow, thymus, and spleen cellular loss. In addition, approximately 10% of AIF+/- females developed perinatal hydrocephaly characterized by brain development impairment, meningeal fibrosis, and medullar hemorrhages; those mice died 5 weeks after birth. AIF+/- with hydrocephaly exhibited loss of ciliated epithelium in the ependymal layer. This phenotype was triggered by the ROS excess. Accordingly, it was possible to diminish the occurrence of hydrocephalus AIF+/- females by supplying dams and newborns with an antioxidant in drinking water. CONCLUSIONS In a single knockout model and at 3 different levels (cell, embryo, and adult mice) we demonstrated that by controlling the mitochondrial OXPHOS/metabolism, AIF is a key factor regulating cell differentiation and fate. Additionally, by providing new insights into the pathological consequences of mitochondrial OXPHOS dysfunction, our new findings pave the way for novel pharmacological strategies.
Collapse
Affiliation(s)
- Laure Delavallée
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Cell Death and Drug Resistance in Hematological Disorders Team, F-75006, Paris, France
| | - Navrita Mathiah
- Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Brussels, Belgium
| | - Lauriane Cabon
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Cell Death and Drug Resistance in Hematological Disorders Team, F-75006, Paris, France
| | - Aurélien Mazeraud
- Experimental Neuropathology Unit, Institut Pasteur, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Neuropathology Service, Sainte-Anne Hospital Center, Paris, France
| | - Marie-Noelle Brunelle-Navas
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Cell Death and Drug Resistance in Hematological Disorders Team, F-75006, Paris, France
| | - Leticia K Lerner
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Cell Death and Drug Resistance in Hematological Disorders Team, F-75006, Paris, France
| | - Mariana Tannoury
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Cell Death and Drug Resistance in Hematological Disorders Team, F-75006, Paris, France
| | - Alexandre Prola
- INSERM UMRS 1180, LabEx LERMIT, Châtenay-Malabry, France; Faculté de Pharmacie, Université Paris-Sud, Châtenay-Malabry, France; Université de Versailles Saint Quentin en Yvelines, Versailles, France; U955-IMRB Team 10 BNMS, INSERM, UPEC, Université Paris-Est, Ecole Nationale Vétérinaire de Maisons-Alfort, France
| | - Raquel Moreno-Loshuertos
- Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain; Instituto de Investigación en Biocomputación y Física de Sistemas Complejos (BiFi), Universidad de Zaragoza, Zaragoza, Spain
| | - Mathieu Baritaud
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Cell Death and Drug Resistance in Hematological Disorders Team, F-75006, Paris, France
| | - Laura Vela
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Cell Death and Drug Resistance in Hematological Disorders Team, F-75006, Paris, France
| | - Kevin Garbin
- Centre de Recherche des Cordeliers, Genotyping and Biochemical facility, INSERM UMRS_1138, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France
| | - Delphine Garnier
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Cell Death and Drug Resistance in Hematological Disorders Team, F-75006, Paris, France
| | - Christophe Lemaire
- INSERM UMRS 1180, LabEx LERMIT, Châtenay-Malabry, France; Faculté de Pharmacie, Université Paris-Sud, Châtenay-Malabry, France; Université de Versailles Saint Quentin en Yvelines, Versailles, France
| | | | - Martine Cohen-Salmon
- Physiology and Physiopathology of the Gliovascular Unit, Collège de France-Center for Interdisciplinary Research in Biology (CIRB)/CNRS UMR 7241/INSERM U1050/Sorbonne Université, Paris, France
| | - Patricio Fernández-Silva
- Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain; Instituto de Investigación en Biocomputación y Física de Sistemas Complejos (BiFi), Universidad de Zaragoza, Zaragoza, Spain
| | - Fabrice Chrétien
- Experimental Neuropathology Unit, Institut Pasteur, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Neuropathology Service, Sainte-Anne Hospital Center, Paris, France
| | - Isabelle Migeotte
- Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Brussels, Belgium
| | - Santos A Susin
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Cell Death and Drug Resistance in Hematological Disorders Team, F-75006, Paris, France.
| |
Collapse
|
6
|
Gjorevski N, Avignon B, Gérard R, Cabon L, Roth AB, Bscheider M, Moisan A. Neutrophilic infiltration in organ-on-a-chip model of tissue inflammation. Lab Chip 2020; 20:3365-3374. [PMID: 32761043 DOI: 10.1039/d0lc00417k] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The multiphasic etiology of tissue inflammation and the fundamental immunological differences between species render inflammatory pathologies difficult to recapitulate in animal models, and account for the paucity of therapies that are successfully translated from rodents to humans. Here, we present a human-relevant organ-on-a-chip platform for experimental inflammatory diseases. We created an immunocompetent in vitro gut model by incorporating intestinal epithelial and immune cells into microfluidic chambers that permit cell movement across an extracellular matrix (ECM) and fluidic channels. This is the first model that integrates a mucosal barrier, a three-dimensional ECM, resident and infiltrating immune cells, and simulates a functional crosstalk that ultimately triggers cellular processes representative of inflammation. Under homeostatic conditions, enterocytes form a tight epithelium and subepithelial macrophages are non-activated. Introduction of pro-inflammatory mediators triggers macrophage activation and inflammation-induced intestinal barrier leakiness. Neutrophils in a parallel, matrix-separated non-epithelial channel are attracted by such a pro-inflammatory microenvironment and migrate through the extracellular matrix, further exacerbating tissue inflammation and damage. With this model, we provide the foundations to recapitulate and investigate the onset of tissue inflammation in a controlled, human-relevant system.
Collapse
Affiliation(s)
- Nikolce Gjorevski
- Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
| | | | | | | | | | | | | |
Collapse
|
7
|
Bertaux A, Cabon L, Brunelle-Navas MN, Bouchet S, Nemazanyy I, Susin SA. Mitochondrial OXPHOS influences immune cell fate: lessons from hematopoietic AIF-deficient and NDUFS4-deficient mouse models. Cell Death Dis 2018; 9:581. [PMID: 29789531 PMCID: PMC5964237 DOI: 10.1038/s41419-018-0583-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Revised: 04/06/2018] [Accepted: 04/10/2018] [Indexed: 02/08/2023]
Affiliation(s)
- Audrey Bertaux
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Sorbonne Université, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France
| | - Lauriane Cabon
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Sorbonne Université, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France
| | - Marie-Noëlle Brunelle-Navas
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Sorbonne Université, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France
| | - Sandrine Bouchet
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Sorbonne Université, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France
| | - Ivan Nemazanyy
- Institut Necker-Enfants Malades (INEM), INSERM U1151, Université Paris Descartes, Sorbonne Paris Cité, 75015, Paris, France
| | - Santos A Susin
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Sorbonne Université, Université Paris Descartes, Sorbonne Paris Cité, 75006, Paris, France.
| |
Collapse
|
8
|
Cabon L, Bertaux A, Brunelle-Navas MN, Nemazanyy I, Scourzic L, Delavallée L, Vela L, Baritaud M, Bouchet S, Lopez C, Quang Van V, Garbin K, Chateau D, Gilard F, Sarfati M, Mercher T, Bernard OA, Susin SA. AIF loss deregulates hematopoiesis and reveals different adaptive metabolic responses in bone marrow cells and thymocytes. Cell Death Differ 2018; 25:983-1001. [PMID: 29323266 PMCID: PMC5943248 DOI: 10.1038/s41418-017-0035-x] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Revised: 09/21/2017] [Accepted: 10/16/2017] [Indexed: 12/13/2022] Open
Abstract
Mitochondrial metabolism is a tightly regulated process that plays a central role throughout the lifespan of hematopoietic cells. Herein, we analyze the consequences of the mitochondrial oxidative phosphorylation (OXPHOS)/metabolism disorder associated with the cell-specific hematopoietic ablation of apoptosis-inducing factor (AIF). AIF-null (AIF-/Y ) mice developed pancytopenia that was associated with hypocellular bone marrow (BM) and thymus atrophy. Although myeloid cells were relatively spared, the B-cell and erythroid lineages were altered with increased frequencies of precursor B cells, pro-erythroblasts I, and basophilic erythroblasts II. T-cell populations were dramatically reduced with a thymopoiesis blockade at a double negative (DN) immature state, with DN1 accumulation and delayed DN2/DN3 and DN3/DN4 transitions. In BM cells, the OXPHOS/metabolism dysfunction provoked by the loss of AIF was counterbalanced by the augmentation of the mitochondrial biogenesis and a shift towards anaerobic glycolysis. Nevertheless, in a caspase-independent process, the resulting excess of reactive oxygen species compromised the viability of the hematopoietic stem cells (HSC) and progenitors. This led to the progressive exhaustion of the HSC pool, a reduced capacity of the BM progenitors to differentiate into colonies in methylcellulose assays, and the absence of cell-autonomous HSC repopulating potential in vivo. In contrast to BM cells, AIF-/Y thymocytes compensated for the OXPHOS breakdown by enhancing fatty acid β-oxidation. By over-expressing CPT1, ACADL and PDK4, three key enzymes facilitating fatty acid β-oxidation (e.g., palmitic acid assimilation), the AIF-/Y thymocytes retrieved the ATP levels of the AIF +/Y cells. As a consequence, it was possible to significantly reestablish AIF-/Y thymopoiesis in vivo by feeding the animals with a high-fat diet complemented with an antioxidant. Overall, our data reveal that the mitochondrial signals regulated by AIF are critical to hematopoietic decision-making. Emerging as a link between mitochondrial metabolism and hematopoietic cell fate, AIF-mediated OXPHOS regulation represents a target for the development of new immunomodulatory therapeutics.
Collapse
Affiliation(s)
- Lauriane Cabon
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris, France
- Sorbonne Universités, Université Pierre et Marie Curie, Paris, France
| | - Audrey Bertaux
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris, France
- Sorbonne Universités, Université Pierre et Marie Curie, Paris, France
| | - Marie-Noëlle Brunelle-Navas
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris, France
- Sorbonne Universités, Université Pierre et Marie Curie, Paris, France
| | - Ivan Nemazanyy
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Laurianne Scourzic
- INSERM U1170, Institut Gustave Roussy, Villejuif, France. Université Paris-Sud/Paris Saclay, Orsay, France
| | - Laure Delavallée
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris, France
- Sorbonne Universités, Université Pierre et Marie Curie, Paris, France
| | - Laura Vela
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris, France
- Sorbonne Universités, Université Pierre et Marie Curie, Paris, France
| | - Mathieu Baritaud
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris, France
- Sorbonne Universités, Université Pierre et Marie Curie, Paris, France
| | - Sandrine Bouchet
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris, France
- Sorbonne Universités, Université Pierre et Marie Curie, Paris, France
| | - Cécile Lopez
- INSERM U1170, Institut Gustave Roussy, Villejuif, France. Université Paris-Sud/Paris Saclay, Orsay, France
| | - Vu Quang Van
- Immunoregulation Laboratory, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
| | - Kevin Garbin
- Sorbonne Universités, Université Pierre et Marie Curie, Paris, France
- Intestine: Nutrition, Barrier, and Diseases Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris, France
| | - Danielle Chateau
- Sorbonne Universités, Université Pierre et Marie Curie, Paris, France
- Intestine: Nutrition, Barrier, and Diseases Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris, France
| | - Françoise Gilard
- Institute of Plant Sciences Paris-Saclay (IPS2), UMR 9213/UMR1403, CNRS, INRA, Université d'Evry, Université Paris-Diderot, Université Paris-Sud/Paris Saclay, Orsay, France
| | - Marika Sarfati
- Immunoregulation Laboratory, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada
| | - Thomas Mercher
- INSERM U1170, Institut Gustave Roussy, Villejuif, France. Université Paris-Sud/Paris Saclay, Orsay, France
| | - Olivier A Bernard
- INSERM U1170, Institut Gustave Roussy, Villejuif, France. Université Paris-Sud/Paris Saclay, Orsay, France
| | - Santos A Susin
- Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris, France.
- Sorbonne Universités, Université Pierre et Marie Curie, Paris, France.
| |
Collapse
|
9
|
Ferreira P, Villanueva R, Martínez-Júlvez M, Herguedas B, Marcuello C, Fernandez-Silva P, Cabon L, Hermoso JA, Lostao A, Susin SA, Medina M. Structural insights into the coenzyme mediated monomer-dimer transition of the pro-apoptotic apoptosis inducing factor. Biochemistry 2014; 53:4204-15. [PMID: 24914854 DOI: 10.1021/bi500343r] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The apoptosis-inducing factor (AIF) is a mitochondrial-flavoprotein that, after cell death induction, is distributed to the nucleus to mediate chromatinolysis. In mitochondria, AIF is present in a monomer-dimer equilibrium that after reduction by NADH gets displaced toward the dimer. The crystal structure of the human AIF (hAIF):NAD(H)-bound dimer revealed one FAD and, unexpectedly, two NAD(H) molecules per protomer. A 1:2 hAIF:NAD(H) binding stoichiometry was additionally confirmed in solution by using surface plasmon resonance. The here newly discovered NAD(H)-binding site includes residues mutated in human disorders, and accommodation of the coenzyme in it requires restructuring of a hAIF portion within the 509-560 apoptogenic segment. Disruption of interactions at the dimerization surface by production of the hAIF E413A/R422A/R430A mutant resulted in a nondimerizable variant considerably less efficiently stabilizing charge-transfer complexes upon coenzyme reduction than WT hAIF. These data reveal that the coenzyme-mediated monomer-dimer transition of hAIF modulates the conformation of its C-terminal proapoptotic domain, as well as its mechanism as reductase. These observations suggest that both the mitochondrial and apoptotic functions of hAIF are interconnected and coenzyme controlled: a key information in the understanding of the physiological role of AIF in the cellular life and death cycle.
Collapse
Affiliation(s)
- Patricia Ferreira
- Departamento de Bioquímica y Biología Molecular y Celular, ‡Instituto de Biocomputación y Física de Sistemas Complejos (BIFI)-Joint Unit BIFI-IQFR (CSIC), and §Laboratorio de Microscopias Avanzadas, Instituto de Nanociencia de Aragón (INA), Universidad de Zaragoza , Zaragoza, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
Apoptosis is nowadays what comes first to your scientist mind when someone mentions cellular suicide. However this is not the sole form of programmed cell death and many other alternative or atypical pathways have now been described. These pathways are indeed rather preferred to apoptosis in some instances based on tissue origin, cell type or development stage of the target cell. In this review, we describe many different programmed cell death subtypes according to their characteristics. Discrete, brutal, final or singular cell death pathways all participate in the elimination of unwanted, damaged or dangerous cells in organisms hence contributing to our knowledge of this particular feature of living beings: dying! Through description of anoikis, necroptosis, entosis, netosis, pyroptosis or ferroptosis, we have no choice but to realize that programmed cell death comes in many flavors.
Collapse
Affiliation(s)
- Lauriane Cabon
- Inserm U872, équipe 19 « mort cellulaire programmée et physiopathologie des cellules tumorales », Centre de recherche des Cordeliers, Université Pierre et Marie Curie, Université Paris-Descartes, Sorbonne-Universités, UMRS 872, 15, rue de l'École de Médecine, 75006 Paris, France
| | - Ana-Carolina Martinez-Torres
- Inserm U872, équipe 19 « mort cellulaire programmée et physiopathologie des cellules tumorales », Centre de recherche des Cordeliers, Université Pierre et Marie Curie, Université Paris-Descartes, Sorbonne-Universités, UMRS 872, 15, rue de l'École de Médecine, 75006 Paris, France
| | - Santos A Susin
- Inserm U872, équipe 19 « mort cellulaire programmée et physiopathologie des cellules tumorales », Centre de recherche des Cordeliers, Université Pierre et Marie Curie, Université Paris-Descartes, Sorbonne-Universités, UMRS 872, 15, rue de l'École de Médecine, 75006 Paris, France
| |
Collapse
|
11
|
Ferreira P, Villanueva R, Cabon L, A. Susin S, Medina M. The Oxido-reductase Activity of the Apoptosis Inducing Factor: A Promising Pharmacological Tool? Curr Pharm Des 2013; 19:2628-36. [DOI: 10.2174/1381612811319140012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2012] [Accepted: 10/30/2012] [Indexed: 11/22/2022]
|
12
|
Baritaud M, Cabon L, Delavallée L, Galán-Malo P, Gilles ME, Brunelle-Navas MN, Susin SA. AIF-mediated caspase-independent necroptosis requires ATM and DNA-PK-induced histone H2AX Ser139 phosphorylation. Cell Death Dis 2012; 3:e390. [PMID: 22972376 PMCID: PMC3461360 DOI: 10.1038/cddis.2012.120] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
The alkylating DNA-damage agent N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) induces a form of caspase-independent necroptosis implicating the mitochondrial flavoprotein apoptosis-inducing factor (AIF). Following the activation of PARP-1 (poly(ADP-ribose) polymerase-1), calpains, BID (BH3 interacting domain death agonist), and BAX (Bcl-2-associated X protein), the apoptogenic form of AIF (tAIF) is translocated to the nucleus where, associated with Ser139-phosphorylated histone H2AX (γH2AX), it creates a DNA-degrading complex that provokes chromatinolysis and cell death by necroptosis. The generation of γH2AX is crucial for this form of cell death, as mutation of H2AX Ser139 to Ala or genetic ablation of H2AX abolish both chromatinolysis and necroptosis. On the contrary, reintroduction of H2AX-wt or the phosphomimetic H2AX mutant (H2AX-S139E) into H2AX−/− cells resensitizes to MNNG-triggered necroptosis. Employing a pharmacological approach and gene knockout cells, we also demonstrate in this paper that the phosphatidylinositol-3-OH kinase-related kinases (PIKKs) ATM (ataxia telangiectasia mutated) and DNA-dependent protein kinase (DNA-PK) mediate γH2AX generation and, consequently, MNNG-induced necroptosis. By contrast, H2AX phosphorylation is not regulated by ATR or other H2AX-related kinases, such as JNK. Interestingly, ATM and DNA-PK phosphorylate H2AX at Ser139 in a synergistic manner with different kinetics of activation. Early after MNNG treatment, ATM generates γH2AX. Further, DNA-PK contributes to H2AX Ser139 phosphorylation. In revealing the pivotal role of PIKKs in MNNG-induced cell death, our data uncover a milestone in the mechanisms regulating AIF-mediated caspase-independent necroptosis.
Collapse
Affiliation(s)
- M Baritaud
- INSERM U872, Programmed cell death and physiopathology of tumor cells. Team n° 19, Centre de Recherche des Cordeliers, Paris, France
| | | | | | | | | | | | | |
Collapse
|
13
|
Van VQ, Baba N, Rubio M, Wakahara K, Panzini B, Richard C, Soucy G, Franchimont D, Fortin G, Torres ACM, Cabon L, Susin S, Sarfati M. CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice. PLoS One 2012; 7:e41972. [PMID: 22870271 PMCID: PMC3411572 DOI: 10.1371/journal.pone.0041972] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2012] [Accepted: 06/29/2012] [Indexed: 12/14/2022] Open
Abstract
How do effector CD4 T cells escape cell death during the contraction of the immune response (IR) remain largely unknown. CD47, through interactions with thrombospondin-1 (TSP-1) and SIRP-α, is implicated in cell death and phagocytosis of malignant cells. Here, we reported a reduction in SIRP-α-Fc binding to effector memory T cells (T(EM)) and in vitro TCR-activated human CD4 T cells that was linked to TSP-1/CD47-induced cell death. The reduced SIRP-α-Fc binding (CD47(low) status) was not detected when CD4 T cells were stained with two anti-CD47 mAbs, which recognize distinct epitopes. In contrast, increased SIRP-α-Fc binding (CD47(high) status) marked central memory T cells (T(CM)) as well as activated CD4 T cells exposed to IL-2, and correlated with resistance to TSP-1/CD47-mediated killing. Auto-aggressive CD4 effectors, which accumulated in lymph nodes and at mucosal sites of patients with Crohn's disease, displayed a CD47(high) status despite a high level of TSP-1 release in colonic tissues. In mice, CD47 (CD47(low) status) was required on antigen (Ag)-specific CD4 effectors for the contraction of the IR in vivo, as significantly lower numbers of Ag-specific CD47(+/+)CD4 T cells were recovered when compared to Ag-specific CD47(-/-) CD4 T cells. In conclusion, we demonstrate that a transient change in the status of CD47, i.e. from CD47(high) to CD47(low), on CD4 effectors regulates the decision-making process that leads to CD47-mediated cell death and contraction of the IR while maintenance of a CD47(high) status on tissue-destructive CD4 effectors prevents the resolution of the inflammatory response.
Collapse
Affiliation(s)
- Vu Quang Van
- Immunoregulation Laboratory, Centre Hospitalier de l’Université de Montréal, Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
| | - Nobuyasu Baba
- Immunoregulation Laboratory, Centre Hospitalier de l’Université de Montréal, Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
| | - Manuel Rubio
- Immunoregulation Laboratory, Centre Hospitalier de l’Université de Montréal, Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
| | - Keiko Wakahara
- Immunoregulation Laboratory, Centre Hospitalier de l’Université de Montréal, Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
| | - Benoit Panzini
- Department of Gastroenterology, Centre Hospitalier de l’Université de Montréal (CHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
| | - Carole Richard
- Department of Digestive Tract Surgery, Centre Hospitalier de l’Université de Montréal (CHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
| | - Genevieve Soucy
- Department of Pathology, Centre Hospitalier de l’Université de Montréal (CHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
| | - Denis Franchimont
- Department de Gastroenterology, Erasme Hospital, Université Libre de Bruxelles (ULB), Bruxelles, Belgique
| | - Genevieve Fortin
- Research Institute of McGill University Health Centre, McGill University, Montreal, Quebec, Canada
| | - Ana Carolina Martinez Torres
- INSERM U872, Mort Cellulaire Programmée et Physiopathologie des Cellules Tumorales, Equipe 19, Centre de Recherche des Cordeliers, Paris, France
- Université Pierre et Marie Curie-Sorbonne Universités, UMRS 872, Paris, France
- Université Paris Descartes, Paris, France
| | - Lauriane Cabon
- INSERM U872, Mort Cellulaire Programmée et Physiopathologie des Cellules Tumorales, Equipe 19, Centre de Recherche des Cordeliers, Paris, France
- Université Pierre et Marie Curie-Sorbonne Universités, UMRS 872, Paris, France
- Université Paris Descartes, Paris, France
| | - Santos Susin
- INSERM U872, Mort Cellulaire Programmée et Physiopathologie des Cellules Tumorales, Equipe 19, Centre de Recherche des Cordeliers, Paris, France
- Université Pierre et Marie Curie-Sorbonne Universités, UMRS 872, Paris, France
- Université Paris Descartes, Paris, France
| | - Marika Sarfati
- Immunoregulation Laboratory, Centre Hospitalier de l’Université de Montréal, Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada
| |
Collapse
|
14
|
Van VQ, Baba N, Rubio M, Wakahara K, Panzini B, Richard C, Susin G, Franchimont D, Fortin G, Martinez Torres AC, Cabon L, Susin S, Sarfati M. CD47low status on CD4 effectors is necessary for the contraction of the immune response in humans and mice (69.13). The Journal of Immunology 2012. [DOI: 10.4049/jimmunol.188.supp.69.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
To execute a memory program, CD4 effector T cells must escape cell death and elimination and survive beyond the contraction of the immune response (IR). The involvement of Fas/FasL in the crash of IR has been challenged and the elimination of CD4 effector T cells appeared to occur independently of caspase activation. We report here that in vitro TCR-activated human CD4 T and ex vivo isolated effector memory T cells displayed a CD47low status that was linked to thrombospondin-1/CD47-induced caspase-independent cell death. By contrast, a CD47highstatus that was observed on central memory T cells and on activated CD4 T cells cultured in the presence of IL-2 correlated with resistance to CD47-mediated killing. A CD47low status was required on murine antigen (Ag)-specific CD4 effectors T cells for the contraction of the IR in vivo, as lower numbers of Ag-specific CD47low CD4 T cells were recovered when compared to Ag-specific CD47-/- CD4 T cells. Finally, the maintenance of a CD47high status on CD4 effectors despite high level of TSP-1 production was observed in inflamed tissues of patients with Crohn’s disease when compared to non-IBD donors, suggesting that a CD47high status on tissue-destructive CD4 effectors prevents the resolution of inflammatory response. In conclusion, a transient change in the status of the self-marker CD47, i.e. from CD47high to CD47low, regulates the decision-making process that leads to cell death during the IR.
Collapse
Affiliation(s)
- Vu Quang Van
- 1Immunoregulation, Centre de Recherche de l'université de Montreal, Montreal, QC, Canada
| | - Nobuyasu Baba
- 1Immunoregulation, Centre de Recherche de l'université de Montreal, Montreal, QC, Canada
| | - Manuel Rubio
- 1Immunoregulation, Centre de Recherche de l'université de Montreal, Montreal, QC, Canada
| | - Keiko Wakahara
- 1Immunoregulation, Centre de Recherche de l'université de Montreal, Montreal, QC, Canada
| | - Benoit Panzini
- 3Digestive tract surgery, Centre de Recherche de l'université de Montreal, Montreal, QC, Canada
| | - Carole Richard
- 4Pathology, Centre de Recherche de l'université de Montreal, Montreal, QC, Canada
| | - Genevieve Susin
- 2Gastroenterology, Centre de Recherche de l'université de Montreal, Montreal, QC, Canada
| | - Denis Franchimont
- 5Gastroenterology, Hôpital Erasme,Université Libre de Bruxelles, Bruxelles, Belgium
| | - Genevieve Fortin
- 6Research Institute of McGill University Health Centre, McGill University, Montreal, QC, Canada
| | | | - Lauriane Cabon
- 7INSERM, Centre de Recherche des Cordeliers, Montreal, QC, Canada
| | - Santos Susin
- 7INSERM, Centre de Recherche des Cordeliers, Montreal, QC, Canada
| | - Marika Sarfati
- 1Immunoregulation, Centre de Recherche de l'université de Montreal, Montreal, QC, Canada
| |
Collapse
|
15
|
Delavallée L, Cabon L, Galán-Malo P, Lorenzo HK, Susin SA. AIF-mediated caspase-independent necroptosis: A new chance for targeted therapeutics. IUBMB Life 2011; 63:221-32. [DOI: 10.1002/iub.432] [Citation(s) in RCA: 127] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2010] [Accepted: 01/26/2011] [Indexed: 02/07/2023]
|